Please assess the completion status of the following clinical trial:

Trial Title: Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* For the healthy, lean individuals:~* Age 18-65 years~* Women: post menopausal (excluding possible menstruation cycle effects)~* Body-mass index (BMI) of \<25 kg/m2,~* Stable bodyweight (\<5% reported change during the previous 3 months).~* Normal fasting and 2h post load glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) (34)~* Right handed~For the obese T2DM individuals:~* Age 18-65 years~* Women: post menopausal (excluding possible menstruation cycle effects)~* BMI 25-40 kg/m2~* Stable bodyweight (\<5% reported change during the previous 3 months).~* Diagnosed with T2DM \> 3 months prior to screening~* HbA1C 6.5-8.5%~* Treatment with metformin at a stable dose for at least 3 months.~* Right handed~For the obese individuals scheduled for gastric bypass surgery:~* Age 18-65 years~* Women: preferably post menopausal (excluding possible menstruation cycle effects)~* Body-mass index (BMI) of \>30 kg/m2,~* Stable bodyweight (\<5% reported change during the previous 1 months).~* Normal or impaired fasting and 2h post load glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) (defined as glucose fasting \< 7.1 mmol/l and after OGTT t=120min \< 11.0 mmol/l) (39)~* Right handed~Exclusion Criteria:~* GLP-1 based therapies, thiazolidinediones, sulphonylurea or insulin within 3 months before screening~* Weight-lowering agents within 3 months before screening.~* Congestive heart failure (NYHA II-IV)~* Chronic renal failure (glomerular filtration rate \< 60 mL/min/1.73m2 per Modification of Diet in Renal Disease (MDRD))~* Liver disease~* History of gastrointestinal disorders (including gastropareses, pancreatitis and cholelithiasis)~* Neurological illness~* Malignancy~* Other type of bariatric surgery (Redo-GBP, sleeve, distal GBP, adj banding, Scopinaro)~* History of major heart disease~* History of major renal disease~* Pregnancy or breast feeding~* Implantable devices~* Substance abuse~* Addiction~* Contra-indication for MRI, such as claustrophobia or pacemaker~* Any psychiatric illness; including eating disorders and depression~* Chronic use of centrally acting agents or glucocorticoids within 2 weeks immediately prior to screening.~* Use of cytostatic or immune modulatory agents~* History or known allergy for acetaminophen.~* History of allergy for insulin analog~* History of allergy for liraglutide~* Participation in other studies~* Individuals who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~* Individuals who are investigator site personnel, directly affiliated with the study, or are immediate family

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): 12 week treatment with liraglutide in fixed dosage
- Insulin glargine (Type: ACTIVE_COMPARATOR): 12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
- before start of treatment period (Type: OTHER): before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).